Long-term calcitonin therapy in postmenopausal osteoporosis.
Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis. All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd. The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline. Although mean total body calcium (TBCa) was not significantly different between treated and control patients throughout the study, mean differences in the change in TBCa from baseline (treated minus control) were significant at 12, 18, and 26 months. The mean slope of TBCa for treated patients, but not for controls, was significantly positive through 18 months. Iliac crest bone biopsies showed (1) a significantly greater percent total bone area in treated compared to control patients at 2 years, and (2) a significantly decreased percent resorbing surface in treated patients when evaluated by paired difference from baseline. At 4 months, serum calcium values were significantly lower in treated patients than in controls (mean difference, treated minus controls), but were not statistically different from controls at study completion. Urine calcium increased significantly for the first 4 months in treated subjects and then declined to baseline levels. Since urinary calcium increased, the increase in TBCa was probably associated with an increase in net intestinal calcium absorption.
D000367:Age Factors; D000368:Aged; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology; D002116:Calcitonin / Q000009:adverse effects / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008593:Menopause; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D011859:Radiography; D013131:Spine / Q000000981:diagnostic imaging
D002116:Calcitonin; D002118:Calcium